“…Sufficient data on the transmission of SARS-CoV-2 to patients by blood products are not yet available. However, during the transplantation process, hepatitis B virus or cytomegalovirus prophylaxis is routinely applied and successful results are obtained [ 9 , 10 ]. It was thought that molnupiravir could prevent the development of infection in the recipient by suppressing viral replication.…”